NICE Turns Attention To Roche's Perjeta After Finally Passing Kadcyla For Breast Cancer

 
• By Sten Stovall
  
Benefit & Cost
NICE finally gave the thumbs up to Roche's Kadcyla for breast cancer

More from Health Technology Assessment

More from Market Access